Revenue
$32.36M
Fiscal year ended 2026-06-30Operating income
$7.53M
Fiscal year ended 2026-06-30Free cash flow
$9.26M
Fiscal year ended 2026-06-30ELITE PHARMACEUTICALS INC /NV/ (ELTP) reported revenue of $32.36M and net income of $5.91M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ELITE PHARMACEUTICALS INC /NV/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.36M | $40.75M | $31.59M | $36.32M | $40.21M | $32.00M | $14.36M | $18.88M | $18.80M | $17.95M |
| Cost of revenue | $18.85M | $19.98M | $18.64M | $22.25M | $12.99M | $14.70M | $8.24M | $10.68M | $10.33M | $9.83M |
| Gross profit | $13.51M | $20.77M | $12.95M | $14.07M | $27.23M | $17.30M | $6.12M | $8.20M | $8.47M | $8.12M |
| Operating income | $7.53M | $10.19M | $9.01M | $8.21M | $21.70M | $11.15M | $1.10M | $3.48M | $3.86M | $3.73M |
| Net income | $5.91M | $18.46M | $18.59M | $13.70M | -$5.88M | $17.00M | -$10.89M | -$11.04M | $615.77K | $3.33M |
| Research & development | $2.03M | $1.64M | $1.04M | $1.39M | $1.67M | $2.04M | $1.79M | $1.97M | $2.16M | $1.72M |
| Weighted-average diluted shares | shares 1.13B | Unavailable | shares 1.14B | shares 1.14B | shares 1.07B | Unavailable | shares 1.07B | shares 1.07B | shares 1.08B | Unavailable |
| Pretax income | $7.72M | $20.85M | $20.83M | $15.69M | -$564.21K | $19.27M | -$10.65M | -$9.52M | $847.75K | $1.99M |
| Income tax expense | $1.81M | $2.39M | $2.24M | $1.99M | $5.32M | $2.27M | $239.18K | $1.52M | $231.98K | -$1.33M |
| Diluted EPS | $0.01 | Unavailable | $0.01 | $0.01 | $-0.01 | Unavailable | $-0.01 | $-0.01 | $0.00 | Unavailable |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $3.55M | $7.70M | $2.47M | $4.03M | $3.40M | $2.03M | $2.72M | $2.27M | $1.97M | $2.24M |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | $7.11M |
| Total assets | $139.67M | $138.29M | $126.41M | $117.25M | $111.34M | $96.39M | $90.76M | $88.20M | $87.85M | $83.65M |
| Current assets | $114.49M | $112.11M | $96.79M | $85.79M | $77.86M | $57.74M | $48.05M | $45.29M | $43.16M | $40.01M |
| Total liabilities | $34.84M | $39.41M | $46.10M | $55.66M | $63.66M | $42.87M | $54.31M | $40.93M | $29.60M | $26.07M |
| Current liabilities | $30.44M | $17.39M | $13.19M | $10.67M | $10.76M | $11.84M | $14.69M | $12.85M | $14.01M | $13.05M |
| Total equity incl. NCI | $104.83M | $98.88M | $80.31M | $61.58M | $47.68M | $53.52M | $36.45M | $47.27M | $58.25M | $57.58M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $24.20M | $21.26M | $25.10M | $18.16M | $19.36M | $16.24M | $20.16M | $14.16M | $13.83M | $12.93M |
| Accounts receivable | $50.44M | $59.72M | $48.53M | $40.87M | $36.22M | $29.21M | $18.45M | $21.44M | $20.49M | $19.45M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $5.59M | $6.05M | $6.52M | $3.42M | $5.09M | $2.96M | $5.84M | $1.98M | $2.61M | $2.71M |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.07M | $9.15M | -$5.28M | $5.10M | $14.78M | $3.92M | -$1.06M | $1.46M | $3.14M | $2.10M |
| Capital expenditures | $808.96K | $398.02K | $206.07K | $103.33K | $218.20K | $754.11K | $0 | $92.44K | $778.53K | $403.65K |
| Investing cash flow | -$808.96K | -$398.02K | -$206.07K | -$103.33K | -$218.20K | -$754.11K | $0 | $17.56K | -$1.66M | -$403.65K |
| Financing cash flow | -$114.59K | -$41.52K | -$33.64K | -$116.47K | -$4.13M | -$137.04K | -$193.10K | -$320.69K | -$174.91K | -$400.97K |
| Net change in cash | $9.15M | $8.71M | -$5.52M | $4.88M | $10.43M | $3.03M | -$1.26M | $1.15M | $1.31M | $1.29M |
| Stock-based compensation | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $252.98K | $369.99K | $268.66K | $275.39K | $275.41K | $290.39K | $313.06K | $227.36K | $322.10K | $380.89K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $9.26M | $8.75M | -$5.48M | $5.00M | $14.56M | $3.16M | -$1.06M | $1.36M | $2.37M | $1.70M |
| Gross margin | 41.7% | 51.0% | 41.0% | 38.7% | 67.7% | 54.1% | 42.6% | 43.4% | 45.1% | 45.2% |
| Operating margin | 23.3% | 25.0% | 28.5% | 22.6% | 54.0% | 34.9% | 7.6% | 18.5% | 20.6% | 20.8% |
| FCF margin | 28.6% | 21.5% | -17.4% | 13.8% | 36.2% | 9.9% | -7.4% | 7.2% | 12.6% | 9.4% |
| SBC / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current ratio | 3.76x | 6.45x | 7.34x | 8.04x | 7.23x | 4.88x | 3.27x | 3.52x | 3.08x | 3.07x |
| Revenue YoY growth | -19.5% | 27.4% | 119.9% | 92.4% | 113.9% | 78.3% | -7.6% | 33.4% | 109.4% | 107.7% |
| Net margin | 18.3% | 45.3% | 58.9% | Unavailable | -14.6% | 53.1% | -75.8% | Unavailable | Unavailable | 18.5% |
| R&D / revenue | 6.3% | 4.0% | 3.3% | 3.8% | 4.2% | 6.4% | 12.5% | 10.4% | 11.5% | 9.6% |
| CapEx / revenue | 2.5% | 1.0% | 0.7% | 0.3% | 0.5% | 2.4% | 0.0% | 0.5% | 4.1% | 2.2% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 23.4% | 11.5% | 10.8% | 12.7% | Unavailable | 11.8% | Unavailable | Unavailable | 27.4% | -66.8% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ELTP in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-13View SEC filing
10-K · Filed 2026-06-29View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-K · Filed 2025-06-30View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.